News

New tests have been added on the Request Form for monitoring of biopharmaceuticals for Therapeutic Drug Monitoring (TDM)

June 4, 2018 - Company News, Product News
New tests have been added on the Request Form for monitoring of biopharmaceuticals for Therapeutic Drug Monitoring (TDM)

NEW tests:
Biopharmaceutical drugs

Monitoring of drug concentration and Anti-Drug Antibodies (ADA):

  • Mabthera® (rituximab) or biosimilars
  • Stelara® (ustekinumab)
  • Roactemra® (tocilizumab)
  • Xolair® (omalizumab)
  • Opdivo® (nivolimumab)

Monitoring of drug concentration:

  • Soliris (eculizumab)
  • Herceptin (trastuzumab)
  • Orencia (abatacept)

The Biopharmaceutical drugs already offered in our portfolio: 

Monitoring of drug concentration and Anti-Drug Antibodies (ADA) or Neutralising Anti-Drug Antibodies (Nabs):

All TNF-alpha inhibitors

  • Remicade (infliximab) or biosimilars
  • Humira (adalimumab)
  • Cimzia (certolizumabpegol)
  • Enbrel (etanercept) or biosimilars
  • Simponi (golimumab)

Monitoring of drug concentration and Anti-Drug Antibodies (ADA):

  • Entyvio® (vedolizumab)

ADA (Anti-Drug Antibodies):

  • Erytropoietin (EPO) 
  • Tysabri® (natalizumab)

Neutralising Anti-Drug Antibodies (Nabs):

  • Interferon-beta

Updated Request Forms

The Request Forms has been updated with the changes stated above.

For more information please contact:

Diagnostic.services@wieslab.com
Lab Manager, Rita Martins Olofsson: + 46 40 - 643 44 12
Key Account Manager, Monica Blixt: +46 708 86 28 10
The Laboratory: +46 40 - 53 76 60

Click the links for more information regarding:

• Sampling instructions
• Request Forms
• Opening hours
• Terms and Conditions

« Back
Clinical studies